Back to Search
Start Over
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy.
- Source :
- Clinical Case Reports; Sep2020, Vol. 8 Issue 9, p1678-1681, 4p
- Publication Year :
- 2020
-
Abstract
- The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20500904
- Volume :
- 8
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Clinical Case Reports
- Publication Type :
- Academic Journal
- Accession number :
- 145960020
- Full Text :
- https://doi.org/10.1002/ccr3.2918